PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 19148296-0 2008 (-)-Epigallocatechin gallate reduces platelet-derived growth factor-BB-stimulated interleukin-6 synthesis in osteoblasts: suppression of SAPK/JNK. epigallocatechin gallate 0-28 interleukin 6 Mus musculus 82-95 19148296-2 2008 In the present study, we investigated whether (-)-epigallocatechin gallate (EGCG), one of the major green tea flavonoids, affects the synthesis of IL-6 in these cells and the mechanism. epigallocatechin gallate 46-74 interleukin 6 Mus musculus 147-151 19148296-2 2008 In the present study, we investigated whether (-)-epigallocatechin gallate (EGCG), one of the major green tea flavonoids, affects the synthesis of IL-6 in these cells and the mechanism. epigallocatechin gallate 76-80 interleukin 6 Mus musculus 147-151 19148296-3 2008 EGCG significantly reduced the IL-6 synthesis and IL-6 mRNA expression stimulated by PDGF-BB, EGCG reduced the PDGF-BB-stimulated IL-6 synthesis also in primary-cultured osteoblasts. epigallocatechin gallate 0-4 interleukin 6 Mus musculus 31-35 19148296-3 2008 EGCG significantly reduced the IL-6 synthesis and IL-6 mRNA expression stimulated by PDGF-BB, EGCG reduced the PDGF-BB-stimulated IL-6 synthesis also in primary-cultured osteoblasts. epigallocatechin gallate 0-4 interleukin 6 Mus musculus 50-54 19148296-3 2008 EGCG significantly reduced the IL-6 synthesis and IL-6 mRNA expression stimulated by PDGF-BB, EGCG reduced the PDGF-BB-stimulated IL-6 synthesis also in primary-cultured osteoblasts. epigallocatechin gallate 0-4 interleukin 6 Mus musculus 50-54 19148296-3 2008 EGCG significantly reduced the IL-6 synthesis and IL-6 mRNA expression stimulated by PDGF-BB, EGCG reduced the PDGF-BB-stimulated IL-6 synthesis also in primary-cultured osteoblasts. epigallocatechin gallate 94-98 interleukin 6 Mus musculus 31-35 19148296-3 2008 EGCG significantly reduced the IL-6 synthesis and IL-6 mRNA expression stimulated by PDGF-BB, EGCG reduced the PDGF-BB-stimulated IL-6 synthesis also in primary-cultured osteoblasts. epigallocatechin gallate 94-98 interleukin 6 Mus musculus 50-54 19148296-3 2008 EGCG significantly reduced the IL-6 synthesis and IL-6 mRNA expression stimulated by PDGF-BB, EGCG reduced the PDGF-BB-stimulated IL-6 synthesis also in primary-cultured osteoblasts. epigallocatechin gallate 94-98 interleukin 6 Mus musculus 50-54 19148296-9 2008 These results strongly suggest that EGCG inhibits the PDGF-BB-stimulated synthesis of IL-6 via suppression of SAPK/JNK pathway in osteoblasts. epigallocatechin gallate 36-40 interleukin 6 Mus musculus 86-90 17350626-0 2007 (-)-Epigallocatechin gallate suppresses endothelin-1-induced interleukin-6 synthesis in osteoblasts: inhibition of p44/p42 MAP kinase activation. epigallocatechin gallate 0-28 interleukin 6 Mus musculus 61-74 17350626-2 2007 In the present study, we investigated the effect of (-)-epigallocatechin gallate (EGCG), one of the major flavonoids containing in green tea, on ET-1-induced IL-6 synthesis in osteoblasts and the underlying mechanism. epigallocatechin gallate 52-80 interleukin 6 Mus musculus 158-162 17350626-2 2007 In the present study, we investigated the effect of (-)-epigallocatechin gallate (EGCG), one of the major flavonoids containing in green tea, on ET-1-induced IL-6 synthesis in osteoblasts and the underlying mechanism. epigallocatechin gallate 82-86 interleukin 6 Mus musculus 158-162 17350626-3 2007 EGCG significantly reduced the synthesis of IL-6 stimulated by ET-1 in MC3T3-E1 cells as well primary cultured mouse osteoblasts. epigallocatechin gallate 0-4 interleukin 6 Mus musculus 44-48 17350626-7 2007 Both the IL-6 synthesis and the phosphorylation of p44/p42 MAP kinase stimulated by 12-O-tetradecanoylphorbol 13-acetate (TPA), a direct activator of PKC, were markedly suppressed by EGCG. epigallocatechin gallate 183-187 interleukin 6 Mus musculus 9-13 17350626-9 2007 These results strongly suggest that EGCG inhibits ET-1-stimulated synthesis of IL-6 via suppression of p44/p42 MAP kinase pathway in osteoblasts, and the inhibitory effect is exerted at a point between PKC and Raf-1 in the ET-1 signaling cascade. epigallocatechin gallate 36-40 interleukin 6 Mus musculus 79-83 33993695-7 2021 EGCG markedly induced the production of cytokines and chemokines in macrophages and mouse peritoneal lavage, including tumor necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1beta), IL-6, CXC chemokine ligands 1 and 2 (CXCL1 and 2), and monocyte chemotactic protein-1 (MCP-1). epigallocatechin gallate 0-4 interleukin 6 Mus musculus 191-195 35409364-8 2022 Furthermore, the suppression of hypoxia-induced IL-6 production by EGCG was mediated via the inhibition of HIF-1alpha expression and the suppression of ROS generation in BV2 cells. epigallocatechin gallate 67-71 interleukin 6 Mus musculus 48-52 35287352-11 2022 Molecular docking results suggest that EGCG has a high affinity for the crystal structure of six targets (IL-6 (interleukin-6), TNF (tumor necrosis factor), Caspase3, MAPK3 (Mitogen-activated protein kinase 3), AKT1, and VEGFA (vascular endothelial growth factor)), and the experimental verification result showed levated expression of these 6 hub targets in the LPS group, but there is an obvious decrease in expression in the LPS + EGCG group. epigallocatechin gallate 39-43 interleukin 6 Mus musculus 106-110 35287352-11 2022 Molecular docking results suggest that EGCG has a high affinity for the crystal structure of six targets (IL-6 (interleukin-6), TNF (tumor necrosis factor), Caspase3, MAPK3 (Mitogen-activated protein kinase 3), AKT1, and VEGFA (vascular endothelial growth factor)), and the experimental verification result showed levated expression of these 6 hub targets in the LPS group, but there is an obvious decrease in expression in the LPS + EGCG group. epigallocatechin gallate 39-43 interleukin 6 Mus musculus 112-125 35287352-15 2022 The anti-inflammatory and anti-apoptotic effects of EGCG occur not only through direct binding to six target proteins (IL-6,TNF-alpha, Caspase3, MAPK3, AKT1, and VEGFA) but also by reducing their expression. epigallocatechin gallate 52-56 interleukin 6 Mus musculus 119-123 34040072-4 2021 EGCG treatment attenuated LPS-stimulated ALI in mice as manifested as improved lung injury scores, decreased total cell amounts, neutrophil amounts and macrophage amounts, inhibited the activity of MPO, decreased wet-to-dry weight ratio of lung tissues, and inhibited release of inflammatory cytokines TNF-alpha, IL-1beta, and IL-6. epigallocatechin gallate 0-4 interleukin 6 Mus musculus 327-331 33868268-6 2021 We measured liver tissue and found that the EGCG gavage treatment significantly inhibited the pro-inflammatory factors (TNF-alpha, IL-1beta, IL-6, MCP-1, MIP-2, IFN-gamma) and oxidation indicators (MPO, NO, ALT, and AST) levels increase. epigallocatechin gallate 44-48 interleukin 6 Mus musculus 141-145 32575718-9 2020 Furthermore, EGCG also reduced the expression of proinflammatory M1 mediators iNOS TNF-alpha, IL-1beta and IL-6 in the LPS administered lung microenvironment. epigallocatechin gallate 13-17 interleukin 6 Mus musculus 107-111 32570121-7 2020 Furthermore, EGCG also significantly prevented the release of H2O2, NOS and 8-isoprostane, and reduced the levels of interleukin (IL)-1beta, IL-2,and IL-6 restrained mice. epigallocatechin gallate 13-17 interleukin 6 Mus musculus 150-154 32908633-8 2020 In addition, EGCG treatment significantly decreased the levels of ROS, MDA, 8-OHdG, IL-1beta, IL-6, and TNF-alpha and increased the levels of CAT and SOD. epigallocatechin gallate 13-17 interleukin 6 Mus musculus 94-98 29428678-8 2018 At 20muM dilution, both CHX and EGCG significantly increased the secretion of IL-1beta, IL-10, IL-12, KC, MIP-1alpha, IFN-gamma and IL-6 (p<0.05). epigallocatechin gallate 32-36 interleukin 6 Mus musculus 132-136 31614951-3 2019 The results indicated the suppressive effect of EGCG on lipid accumulation, pro-inflammatory cytokines (TNF-alpha, IL-6, and IL-1beta) release, and microglial activation in both cellular and high-fat-diet rodent models. epigallocatechin gallate 48-52 interleukin 6 Mus musculus 115-119 31362373-9 2019 In addition, EGCG treatment attenuated colon inflammation by suppressing colonic levels of pro-inflammatory cytokines IL-6, MCP-1, and TNF-alpha, and inhibited CD3+ T cell and CD68+ macrophage infiltration. epigallocatechin gallate 13-17 interleukin 6 Mus musculus 118-122 31241712-8 2019 In addition, EGCG significantly decreased the expression of pro-inflammatory cytokines tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, and IL-6 in the lung, serum, and bronchoalveolar lavage fluid, and alleviated the expression of TLR-4, MyD88, TRIF, and p-p65 in the lung tissue. epigallocatechin gallate 13-17 interleukin 6 Mus musculus 150-154 29916550-9 2018 EGCG 20 mg/kg significantly reduced asthmatic symptoms, lung inflammatory cell infiltration, and the inflammatory factor levels of interleukin (IL)-2, IL-6 and tumor necrosis factor (TNF)-alpha. epigallocatechin gallate 0-4 interleukin 6 Mus musculus 151-155 32545266-7 2020 In addition, EGCG inhibited IL-6-induced hepcidin expression, which was reversed by SMILE knockdown. epigallocatechin gallate 13-17 interleukin 6 Mus musculus 28-32 32545266-9 2020 These results reveal a previously unrecognized role of EGCG-inducible SMILE in the IL-6-dependent transcriptional regulation of iron metabolism. epigallocatechin gallate 55-59 interleukin 6 Mus musculus 83-87 30783194-9 2019 Th-17 associated pro-inflammatory gene [interleukin 1 beta (IL-1beta), IL-6, IL-17A, and tumor necrosis factor alpha (TNF-alpha)] expressions were down regulated by GTE and EGCG treatments, which showed no detectable morphological defects in liver and kidney in non-induced and EAU mice. epigallocatechin gallate 165-168 interleukin 6 Mus musculus 71-75 30783194-9 2019 Th-17 associated pro-inflammatory gene [interleukin 1 beta (IL-1beta), IL-6, IL-17A, and tumor necrosis factor alpha (TNF-alpha)] expressions were down regulated by GTE and EGCG treatments, which showed no detectable morphological defects in liver and kidney in non-induced and EAU mice. epigallocatechin gallate 173-177 interleukin 6 Mus musculus 71-75 29593532-9 2018 Results: EGCG administration markedly attenuated atherosclerotic plaque formation in HFD-fed ApoE-/- mice, which were accompanied by increased plasma interleukin-10 (IL-10) level and decreased plasma IL-6 and tumor necrosis factor-alpha (TNF-alpha) levels. epigallocatechin gallate 9-13 interleukin 6 Mus musculus 200-204 29363729-4 2018 Flow cytometric analysis indicated that the ratio of CD3+CD4+ to CD3+CD8+ T lymphocytes in the peripheral blood increased in MPTP-treated mice following treatment with EGCG, and EGCG reduced expression of inflammatory factors tumor necrosis factor-alpha and interleukin-6 in serum. epigallocatechin gallate 178-182 interleukin 6 Mus musculus 258-271 28558302-5 2017 After administration of EGCG, the number of sneezes and the occurrence of nasal rubbing were significantly decreased, the concentrations of immunoglobulin E (IgE) and histamine were suppressed in AR mouse serum, the levels of interleukin (IL)-1beta, IL-4, and IL-6 were reduced in AR mice nasal lavage fluid (NLF), and the nasal mucosa mRNA and protein expression of cyclooxygenase 2 (COX-2), IL-1beta, IL-4, and IL-6 were inhibited. epigallocatechin gallate 24-28 interleukin 6 Mus musculus 260-264 29862488-13 2018 In addition, EGCG treatment decreased the circulat-ing tumour necrosis factor-alpha, interleukin-6, monocyte chemoattractant protein-1, and interferon-gamma levels in apolipoprotein E-deficient mice. epigallocatechin gallate 13-17 interleukin 6 Mus musculus 85-98 28558302-5 2017 After administration of EGCG, the number of sneezes and the occurrence of nasal rubbing were significantly decreased, the concentrations of immunoglobulin E (IgE) and histamine were suppressed in AR mouse serum, the levels of interleukin (IL)-1beta, IL-4, and IL-6 were reduced in AR mice nasal lavage fluid (NLF), and the nasal mucosa mRNA and protein expression of cyclooxygenase 2 (COX-2), IL-1beta, IL-4, and IL-6 were inhibited. epigallocatechin gallate 24-28 interleukin 6 Mus musculus 413-417 23851196-0 2013 (-)-Epigallocatechin gallate amplifies interleukin-1-stimulated interleukin-6 synthesis in osteoblast-like MC3T3-E1 cells. epigallocatechin gallate 0-28 interleukin 6 Mus musculus 64-77 26929598-6 2016 EGCG decreased the immunoreaction and pathological damage by reducing inflammatory factors, such as TNF-alpha, IL-6, IFN-gamma, and IL-1beta. epigallocatechin gallate 0-4 interleukin 6 Mus musculus 111-115 26929598-7 2016 EGCG also exhibited an antiapoptotic and antiautophagic effect by inhibiting BNIP3 via the IL-6/JAKs/STAT3 pathway. epigallocatechin gallate 0-4 interleukin 6 Mus musculus 91-95 26929598-8 2016 CONCLUSION: EGCG attenuated liver injury in ConA-induced hepatitis by downregulating IL-6/JAKs/STAT3/BNIP3-mediated apoptosis and autophagy. epigallocatechin gallate 12-16 interleukin 6 Mus musculus 85-89 26643169-7 2016 Our results indicated that EGCG significantly suppressed the expression of tumor necrosis factor alpha (TNFalpha), interleukin-1beta, interleukin-6, and inducible nitric oxide synthase (iNOS) in Abeta-stimulated EOC 13.31 microglia. epigallocatechin gallate 27-31 interleukin 6 Mus musculus 134-147 27218415-6 2016 EGCG also decreased colonic protein levels of IL-1beta, IL-6, and tumor necrosis factor-alpha, as well as colonic lipid peroxides compared to DSS-treated controls. epigallocatechin gallate 0-4 interleukin 6 Mus musculus 56-93 27234527-8 2016 Furthermore, EGCG decreased MSU-triggered neutrophil cytosolic factor 1 and NLRP3 protein expression, limiting pro-inflammatory mediator secretion such as IL-1beta, IL-6, monocyte chemoattractant protein-1, and serum amyloid A. epigallocatechin gallate 13-17 interleukin 6 Mus musculus 165-169 27744729-9 2016 Consequently, EGCG pretreatment can effectively inhibit the Th17-related pro-inflammatory cytokine (e.g. IL-17 and IL-6) upregulation induced by TP treatment. epigallocatechin gallate 14-18 interleukin 6 Mus musculus 115-119 26668622-0 2015 Epigallocatechin-3-gallate-induced inhibition of interleukin-6 release and adjustment of the regulatory T/T helper 17 cell balance in the treatment of colitis in mice. epigallocatechin gallate 0-26 interleukin 6 Mus musculus 49-62 26668622-8 2015 EGCG could reduce the release of IL-6 and IL-17 and regulate the mouse splenic regulatory T-cell (Treg)/T helper 17 cell (Th17) ratio, while increasing the plasma levels of IL-10 and TGF-beta1 and decreasing the HIF-1alpha and STAT3 protein expression in the colon. epigallocatechin gallate 0-4 interleukin 6 Mus musculus 33-37 26668622-9 2015 The experiments confirmed that EGCG treated mice with experimental colitis by inhibiting the release of IL-6 and regulating the body Treg/Th17 balance. epigallocatechin gallate 31-35 interleukin 6 Mus musculus 104-108 26496857-0 2015 Amplification by (-)-epigallocatechin gallate and chlorogenic acid of TNF-alpha-stimulated interleukin-6 synthesis in osteoblasts. epigallocatechin gallate 17-45 interleukin 6 Mus musculus 91-104 26496857-4 2015 In the present study, the effects of EGCG and CGA on the TNF-alpha-stimulated interleukin-6 synthesis were investigated in MC3T3-E1 cells. epigallocatechin gallate 37-41 interleukin 6 Mus musculus 78-91 26496857-5 2015 EGCG and CGA significantly enhanced TNF-alpha-stimulated interleukin-6 release. epigallocatechin gallate 0-4 interleukin 6 Mus musculus 57-70 26496857-6 2015 In addition, the interleukin-6 mRNA expression levels induced by TNF-alpha were supported by EGCG, as well as CGA. epigallocatechin gallate 93-97 interleukin 6 Mus musculus 17-30 26496857-8 2015 These results strongly suggest that EGCG and CGA enhance the TNF-alpha-stimulated interleukin-6 synthesis in osteoblasts, and that the amplifying effect of EGCG, but not CGA, is exerted via inhibiting p70 S6 kinase. epigallocatechin gallate 36-40 interleukin 6 Mus musculus 82-95 23851196-4 2013 In the present study, we investigated the effect of EGCG on the IL-1 stimulated IL-6 synthesis in osteoblast-like MC3T3-E1 cells. epigallocatechin gallate 52-56 interleukin 6 Mus musculus 80-84 23851196-5 2013 EGCG significantly enhanced the IL-1-stimulated IL-6 synthesis in a dose-dependent manner in the range between 50 and 100 muM. epigallocatechin gallate 0-4 interleukin 6 Mus musculus 48-52 23851196-6 2013 EGCG increased the mRNA levels of IL-6 stimulated by IL-1. epigallocatechin gallate 0-4 interleukin 6 Mus musculus 34-38 23851196-9 2013 These results strongly suggest that EGCG enhances IL-1-stimulated IL-6 synthesis through inhibiting the AMPK-IkappaB/NF-kappaB pathway at the point between AMPK and IkappaB/NF-kappaB in osteoblasts. epigallocatechin gallate 36-40 interleukin 6 Mus musculus 66-70 24044575-12 2013 Ex vivo incubation of TAM with exosomes from EGCG-treated 4T1 cells led to IKKalpha suppression and concomitant I-kappaB accumulation; increase of IL-6 and TGF-beta; and, decrease of TNF-alpha. epigallocatechin gallate 45-49 interleukin 6 Mus musculus 147-151 24044575-10 2013 Expression of chemokine for monocytes (CSF-1 and CCL-2) were low in tumor cells from EGCG-treated mice, and cytokines of TAM was skewed from M2- into M1-like phenotype by EGCG as evidenced by decreased IL-6 and TGF-beta and increased TNF-alpha. epigallocatechin gallate 85-89 interleukin 6 Mus musculus 202-206 22570747-4 2012 RESULTS: EGCG inhibited accumulation of LPS-induced IL-12p40, IL-6, MCP-1, ICAM-1, and VCAM-1 mRNA in BMMs. epigallocatechin gallate 9-13 interleukin 6 Mus musculus 62-66 23064699-3 2013 In this study, we investigated how EGCG impacts differentiation of naive CD4(+) T cells into different effector lineages and report that EGCG impeded Th1, Th9, and Th17 differentiation and prevented IL-6-induced suppression of Treg development. epigallocatechin gallate 35-39 interleukin 6 Mus musculus 199-203 23064699-3 2013 In this study, we investigated how EGCG impacts differentiation of naive CD4(+) T cells into different effector lineages and report that EGCG impeded Th1, Th9, and Th17 differentiation and prevented IL-6-induced suppression of Treg development. epigallocatechin gallate 137-141 interleukin 6 Mus musculus 199-203 23064699-6 2013 EGCG-induced change in Th17/Treg balance may be mediated by its inhibition of IL-6 signaling because EGCG inhibited soluble IL-6R, membrane gp130, and IL-6-induced phosphorylation of STAT3. epigallocatechin gallate 0-4 interleukin 6 Mus musculus 78-82 23064699-6 2013 EGCG-induced change in Th17/Treg balance may be mediated by its inhibition of IL-6 signaling because EGCG inhibited soluble IL-6R, membrane gp130, and IL-6-induced phosphorylation of STAT3. epigallocatechin gallate 0-4 interleukin 6 Mus musculus 124-128 23064699-6 2013 EGCG-induced change in Th17/Treg balance may be mediated by its inhibition of IL-6 signaling because EGCG inhibited soluble IL-6R, membrane gp130, and IL-6-induced phosphorylation of STAT3. epigallocatechin gallate 101-105 interleukin 6 Mus musculus 78-82 23064699-6 2013 EGCG-induced change in Th17/Treg balance may be mediated by its inhibition of IL-6 signaling because EGCG inhibited soluble IL-6R, membrane gp130, and IL-6-induced phosphorylation of STAT3. epigallocatechin gallate 101-105 interleukin 6 Mus musculus 124-128 20140007-8 2010 EGCG activated AMPK and blocked LPS/IFN-gamma-induced inflammatory mediator production (iNOS expression, supernatant NO and interleukin-6). epigallocatechin gallate 0-4 interleukin 6 Mus musculus 124-137 21498061-8 2011 Moreover GTP and its bioactive components (catechin, epigallocatechin and epigallocatechin-3-gallate) assisted in decreasing the leukocytopenia seen after whole mice irradiation and significantly reduced the elevated serum inflammatory cytokines (TNF-alpha, IL-1beta, and IL-6). epigallocatechin gallate 74-100 interleukin 6 Mus musculus 272-276 19822443-4 2010 A significant and dose-dependent inhibition of IL-4-induced IL-6 expression was observed in HAEC pre-treated with antioxidants, such as pyrrolidine dithiocarbamate (PDTC) and epigallocatechin gallate (EGCG), indicating that IL-4-induced IL-6 expression is mediated via an ROS-dependent mechanism. epigallocatechin gallate 175-199 interleukin 6 Mus musculus 60-64 19822443-4 2010 A significant and dose-dependent inhibition of IL-4-induced IL-6 expression was observed in HAEC pre-treated with antioxidants, such as pyrrolidine dithiocarbamate (PDTC) and epigallocatechin gallate (EGCG), indicating that IL-4-induced IL-6 expression is mediated via an ROS-dependent mechanism. epigallocatechin gallate 175-199 interleukin 6 Mus musculus 237-241 19822443-4 2010 A significant and dose-dependent inhibition of IL-4-induced IL-6 expression was observed in HAEC pre-treated with antioxidants, such as pyrrolidine dithiocarbamate (PDTC) and epigallocatechin gallate (EGCG), indicating that IL-4-induced IL-6 expression is mediated via an ROS-dependent mechanism. epigallocatechin gallate 201-205 interleukin 6 Mus musculus 60-64 19822443-4 2010 A significant and dose-dependent inhibition of IL-4-induced IL-6 expression was observed in HAEC pre-treated with antioxidants, such as pyrrolidine dithiocarbamate (PDTC) and epigallocatechin gallate (EGCG), indicating that IL-4-induced IL-6 expression is mediated via an ROS-dependent mechanism. epigallocatechin gallate 201-205 interleukin 6 Mus musculus 237-241 18500674-0 2008 (-)-Epigallocatechin gallate inhibits basic fibroblast growth factor-stimulated interleukin-6 synthesis in osteoblasts. epigallocatechin gallate 0-28 interleukin 6 Mus musculus 80-93 19883714-11 2010 EGCG also increased plasma interleukin-6 and monocyte chemoattractant protein-1. epigallocatechin gallate 0-4 interleukin 6 Mus musculus 27-40 18500674-2 2008 In the present study, we investigated the exact mechanism of IL-6 and the effects of (-)-epi-gallocatechin gallate (EGCG), one of the major green tea flavonoids, on the synthesis of IL-6. epigallocatechin gallate 85-114 interleukin 6 Mus musculus 182-186 18500674-2 2008 In the present study, we investigated the exact mechanism of IL-6 and the effects of (-)-epi-gallocatechin gallate (EGCG), one of the major green tea flavonoids, on the synthesis of IL-6. epigallocatechin gallate 116-120 interleukin 6 Mus musculus 182-186 18500674-4 2008 EGCG significantly reduced the IL-6 synthesis stimulated by FGF-2 in a dose-dependent manner. epigallocatechin gallate 0-4 interleukin 6 Mus musculus 31-35 18500674-6 2008 These results strongly suggest that EGCG inhibits the FGF-2-stimulated synthesis of IL-6 at least partly via suppression of the p44/p42 MAP kinase pathway and the p38 MAP kinase pathway in osteoblasts. epigallocatechin gallate 36-40 interleukin 6 Mus musculus 84-88 21479417-7 2008 In addition, treatment with EGCG or Poly E decreased the protein and mRNA expression levels of Cyclooxygenase (COX)-2 and the mRNA expression of inflammatory cytokines (TNF-alpha, IFN-gamma, IL-6, IL-12 and IL-18) in the colonic mucosa. epigallocatechin gallate 28-32 interleukin 6 Mus musculus 191-195